this the quick of seen momentum in with a payer James. review Thanks, and product then will overview status portfolio across our quarter. start I
with on start Let's and access payer updates XX. Slide
Starting maintained across all and have progress. in product at Caremark major payers to continue ANNOVERA the added portfolio August. We ANNOVERA, make status with non-preferred
fee-for-service. as X. ANNOVERA West with progress who moved Medicaid Medicaid. made as coverage unrestricted for to XX% had We win ANNOVERA added has Medi-Cal made October X additional non-preferred Virginia is insurance also for with of BIJUVA November commercial. has of BIJUVA from an as X, and We October preferred Anthem, of
XX. Let's Slide move to
for Now strong payer birth we with the of that supporting favorable access ANNOVERA, ANNOVERA. flagship out at low state coverage pocket for product control costs let's our are strong combined have for look how laws
First, is NuvaRing than when same an cost looking or generic a the top the the commercial at less basis. ANNOVERA of for annual for on cross-section payers,
and this that zero utilized patient XX% We out $X the is of paid the protection they hub the patient data of out pocket our of We patients patients of pocket care from fill. for data In that where have vitaCare. $XX representative is annual addition, our ANNOVERA. believe of between data showing all and regardless know pay X,XXX XX% of and patients,
we reason Slide with to XX. by have we pleased I commercial will ANNOVERA. move this will am of believe ring one significant this payer shift formulary, benefit the from payer. XX% The of in lives vaginal the and NuvaRing is be that to managers an Let's managed is ANNOVERA contraceptive share pharmaceutical this announce that begin ANNOVERA will for which only to be January. for branded PBM’s XXXX opportunity are preferred also preferred in which market with top means coverage that a will key excluded provides approximately competitors the be gained removed.
to class, VVA from all Moving will will same Premarin Intrarosa. gained IMVEXXY be as the branded the the the XXXX PBM’s with XX, such cream, preferred and PBM for be Slide and on Osphena coverage pharmaceutical Estring formulary also formulary. only excluded
for you that branded-pharmaceutical share shift IMVEXXY. class, to the in only represents also market in in remind an share XX% opportunity market Premarin third over the I this a the quarter. would As VVA like national had
the I'd patients. co-pay by of impact continued utilization this gears, COVID-XX the how of are addition, being of our preferred, like provide we In these will proactively context to environment. reduce changing program navigating some for and Switching
to two ways. Turning COVID us impact continues to XX, in Slide
in GYN lower First, patient levels. visits This results behavior switching into brands. OB continue be new than to to offices and pre-COVID less
target levels. access prescribers our access our in pre-COVID continue its is for maximum in while saw to second had May. and still from significantly the is growth for down limited to QX is prescriber record we quarter QX. ANNOVERA, chart sales be with across for portfolio that from access shows this, The on The have believe increasing Despite base, a we more impact force full
we ways that educational and our their those Turning patients to to accomplishing to in engage are consumer to initiatives are and if how essentially our plans adapted not virtually, innovative person. our growth have even in access we Slide they across initiatives, provider allow gain customer XX, in this prescriber seeing so environment, as programs products, base
Slide is side. patients prescriptions the to XX, ANNOVERA results filled by quarterly total on on Moving left-hand
approximately ANNOVERA results place X,XXX coming at quarter. the plan the the over you Unapologetically in see than activated quarter for for launch third in second prescriptions our time, with These full As can reflect campaign. the and quarter, third total consumer first doubled more in the
our expansion to and breadth both during of improvement prescribers addition, our significantly us prescribers allowed to in depth. from from quarter, pre-COVID access the In salesforce was but the in continue down base increased second quarter, to levels. writer access The
strong at was in mentioned, August status at net added per as remains non-preferred $X,XXX. Caremark Finally, ANNOVERA to unit and revenue CVS
our the Slide at to more the left-hand detail. in of the the number the side writers doubled XX, quarter, slide, Turning Starting over let's second see look quarter. on base writer third overall of can in you
of side we right-hand an as the trend the the opportunity slide, early we to also A of brand did not writers, for Moving loyalty. improved and writer indicator of growing health. we only look key number double
to provider. from their activating to an uptake we on of placing to XX the Turning Slide maximize ANNOVERA emphasis consumer ANNOVERA, are request
key You they is to that the category a right want market with willingness element unique on birth while method patients before the advertising dynamic contraceptive control the ask of chart grow prescribe can have that their seeing ANNOVERA. in knowing direct-to-consumer prioritized the of prescriber. ANNOVERA XX% The is for physician to women to we see This as the product. illustrates majority this
is to next first Campaign, The XXXX. on Influencer important including launched ANNOVERA our is given importance our the our phase spokesperson. scheduled of and July endorsement Turning Unapologetically continue to in category. XX, birth This control the campaign is of rollout peer-to-peer consumer consumer into the an initiative Slide celebrity X,
channel focus for to We the and to grow continue will the industry as continues for also on ANNOVERA. telemedicine,
our continuing messaging heavily Moving focused XX, campaign, in to the through on are identify messaging. Slide helping value a perspective, focused types of prescribers appropriate are From to to patient the the educate we key consumer we addition ANNOVERA. on prescriber on
to challenge, efforts, medical XX to education providers Finally, have attendees, speaker programs proved which on over to-date. XXX with with virtual with we access press continue valuable,
which volume refills, in to be Turning is for significant as out believe years us another Slide ANNOVERA ANNOVERA will XX, significant for grows. driver the we
The patients refills are in out the starting in to the of done our refill that of being the next pocket acceptability patient XX% in are conducted opportunity mentioned robust council. we so. that this by due patients is this I to confident quarter very cost prior. confident Approximately of refills experienced eligible that of early have over data we to refills occur. is women actual Last, the are the on a in X,XXX have by study translating are low to reason population We
and Slide XX, To health, experienced the multiple-channels, telemedicine. begin have grow access COVID, working growth partners in to segments, public multiple-channels. are military catalyst channels for a of the to the The Moving in-clinics of with to ANNOVERA the and the and is slowdown each open. another relevant leading distributors across with but we continued both as basic to progress pull-through make public due health military have and we
our products. let's Now review Menopausal
increased Moving to prescriptions, on total the is The prescriptions rebound side. Slide which starting quarterly is to drive total continued NRx XX, filled patients IMVEXXY left-hand to of by XXX,XXX. XX%
quarter, quarter. third New over for the prescriptions increased second XX% the
drivers performance Moving that in to like right-hand growth. now resulted our the review side, I the would to
Care drive Sex activated of mind Care is of IMVEXXY. consumer First, top our in awareness campaign to August Self we
continue approximately prescriptions XX% In in average resulting new addition, per base, writer the we in our of prescriber. to increase number expand
to Finally, per unit net revenue improved $XX.
is gross during Our net from the improve that XXXX. goal to to
We card including have commercial January changes the co-pay program. several and our cash drive enhanced receive and key per improvement that that will levers the in we in coverage unit, net to to revenue
access Slide plan media and campaign expanding generate Turning patients. and for deliver on in XX, consumer initiatives social quarter to in continue messaging reminds of strong to our on focus that we addition, to XXXX, support access the on co-pay of fourth IMVEXXY. to prescriber into awareness plan support We our other and open to
IMVEXXY stated in January. PBMs BIJUVA. competitors, share. access total key XX% I'd including to in will Premarin quickly prescription of preferred as currently In one remove gain top will the at touch like addition, on This market
at in to the with with BIJUVA for sales XX% and XX, growth we Slide TRx and to the in both respectively. to deemphasize see continue field, NRx and even decision XX% Turning quarter representatives seven our BIJUVA only promoting
a the We are continuing modest continued trend this in this upward with approach for and quarter. quarter anticipate fourth
third quarter $XX. improved the unit net to revenue per During
Moving the to including for which NASEM that Report. the and FDA continue that the commissioned the we Engineering A as is referred the Slide Sciences, to mention report environment increased practices, XX, on I articulates of to regulation. want by monitor to National Academies need Medicine for the category, compounding
have topic been over BIO-IGNITE like the FDA. to No continue scheduled for will regardless our support I We to Rob yet customers around this of now it to changes. any remarks. by meetings would closing turn
